CANCER THERAPIES
IO SOLUTIONS PORTFOLIO
VIRTUAL EVENTS
LATEST EVIDENCE
CANCER THERAPIES
IO SOLUTIONS PORTFOLIO
VIRTUAL EVENTS
LATEST EVIDENCE
Interventional Radiology / Interventional Oncology / Latest Evidence

Interventional Oncology Latest Evidence


Forging clinical partnerships investing in investigator-initiated research


We work with you and invest in research to provide the evidence you need to be confident in recommending proven interventional oncology strategies to your peers and your patients.


Clinical evidence with TheraSphereTM in liver cancer

For 20 years, we have been making significant investments in advancing clinical data for TheraSphereTM (Y90 SIRT treatment) building evidence of the benefits it offers and increasing our understanding of how to optimise personalised treatment strategies in the treatment of primary liver cancer (hepatocellular carcinoma and cholangiocarcinoma) and of mCRC (colorectal cancer that has metastasised to the liver). Beginning with more advanced stage patients to early-stage HCC with low tumour burden. From bridging and downstaging to lobectomy and segmentectomy, the versatility of TheraSphereTM Y90 Microspheres has been proven in more than 50 publications, and more data is on its way….

 
EPOCH Trial
 

DOSISPHERE-01

Multi-centre, randomised phase II study: TheraSphereTM with standard vs personalised dosimetry in patients with advanced HCC.

Dosisphere 01 Trial

LEGACY

Robust multicenter study confirming TheraSphereTM as a neoadjuvant or standalone therapy in treating unresectable solitary HCC.

Legacy study

TARGET

A global retrospective study that confirms TheraSphereTM for HCC as safe and effective, demonstrating predictable clinical outcomes across a broad patient population.
Target study
 


Clinical Evidence for Cryoablation


We invest in exploring new cryoablation treatment options for our clinicians and patients in the fight against different types of cancer.

Cryoablation is a minimally invasive and safe alternative to surgery. This therapy is also an alternative for patients who suffer from renal cell carcinoma, lung or prostate cancer and muskuloeskeletal tumours, among others.

Top